Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB

AS Whitehouse and MJ Tisdale

Proteolysis-inducing factor (PIF), isolated from a cachexia-inducing murine tumour, has been shown to stimulate protein breakdown in C2C12 myotubes. The effect was attenuated by the specific proteasome inhibitor lactacystin and there was an elevation of proteasome 'chymotrypsin-like' enzyme activity and expression of 20S proteasome β-subunits at concentrations of PIF between 2 and 16 nM. Higher concentrations of PIF had no effect. The action of PIF was attenuated by eicosapentaenoic acid (EPA) (50 μM). At a concentration of 4 nM, PIF induced a transient decrease in lxBα levels after 30 min incubation, while no effect was seen at 20 nM PIF. The level of lxBα, an NF-κB inhibitory protein, returned to normal after 60 min. Depletion of lxBα from the cytosol was not seen in myotubes pretreated with EPA, suggesting that the NF-κB/lxB complex was stabilised. At concentrations between 2 and 8 nM, PIF stimulated an increased nuclear migration of NF-κB, which was not seen in myotubes pretreated with EPA. The PIF-induced increase in chymotrypsin-like enzyme activity was also attenuated by the NF-κB inhibitor peptide SNS0, suggesting that NF-κB may be involved in the PIF-induced increase in proteasome expression. The results further suggest that EPA may attenuate protein degradation induced by PIF, at least partly, by preventing NF-κB accumulation in the nucleus.

Keywords: cachexia; protein catabolism; proteolysis-inducing factor; EPA; NF-κB; proteasome expression

Loss of protein from skeletal muscle is a common phenomenon associated with a number of catabolic conditions. Of the proteolytic pathways, the lysosomal (cathepsins) and the calcium-dependent cysteine proteases (calpains) contribute between 15 and 20% of total protein breakdown in muscles (Lecker et al., 1999). Muscle wasting in starvation (Wing and Goldberg, 1993), sepsis (Tiao et al., 1994), metabolic acidosis (Mitch et al., 1994), weightlessness (Taillandier et al., 1996), severe trauma (Biolo et al., 2000), denervation atrophy (Medina et al., 1995) and cancer cachexia, in both mice (Lorite et al., 1998) and humans (Williams et al., 1999) has been attributed to upregulation of ATP-ubiquitin-dependent proteolysis (ubiquitin–proteasome). In this process, proteins are tagged for degradation by the attachment of a polyubiquitin chain, which is recognised by the 26S proteasome, a large multisubunit catalytic complex. However, the ubiquitin–proteasome pathway does not disassemble myofibrils directly and the calcium–calpain pathway has been suggested to release myofilaments from the sarcomere before myosin can be degraded by the proteasome (Hasselgren and Fischer, 2001).

Muscle protein degradation in cancer cachexia appears to be associated with a sulphated glycoprotein of Mr 24 000 secreted by cachexia-inducing murine and human tumours (Todorov et al., 1996a; Cabal-Manzano et al., 2001). This substance is capable of inducing muscle protein breakdown directly, both in vitro and in vivo (Lorite et al., 1997), and has been named proteolysis-inducing factor (PIF). PIF has been detected in the urine of weight-losing patients with carcinoma of the pancreas, breast, ovary, lung, colon, rectum and liver (Cariuk et al., 1997). Patients with pancreatic cancer excreting PIF in the urine had a significantly greater total weight loss and rate of weight loss than patients whose urine did not contain PIF (Wigmore et al., 2000). Protein degradation induced by PIF, both in gastrocnemius muscle in vivo and murine myoblasts in vitro, is associated with increased levels of both mRNA and protein for the Mr 14 000 ubiquitin conjugating protein and proteasome α and β subunits (Lorite et al., 2001), suggesting that the ubiquitin–proteasome proteolytic pathway plays a major role in the action of PIF. The induction of protein degradation by PIF has been shown to be completely attenuated by pretreatment with eicosapentaenoic acid (EPA) (Lorite et al., 1997), which has been shown to downregulate expression of the key regulatory components of the ubiquitin–proteasome pathway in skeletal muscle of mice bearing the MAC16 tumour (Whitehouse et al., 2001a).

Although PIF has been shown to upregulate expression of the ubiquitin–proteasome proteolytic pathway in murine myotubes (Gomes-Marcondes et al., 2002), there is no information, to date, on nuclear transcription factors involved. In primary hepatocytes and the human cancer cell line Hep G2, PIF has been shown to activate the transcription factor nuclear factor-kappa B (NF-κB) resulting in the increased production of interleukin-8 (IL-8), interleukin-6 (IL-6) and C-reactive protein, and the decreased
production of transferrin (Watchorn et al., 2001). There was also an increase in ICAM-1, another NF-κB inducible gene. Protein degradation induced by TNF-α in murine myotubes also appears to arise from an increase in ubiquitin-dependent proteolysis (Li et al., 1998) and studies in transfected cells containing mutant IκB proteins insensitive to degradation suggested that NF-κB was an essential mediator of the TNF-α-induced protein breakdown (Li and Read, 2000). This suggests that the induction of protein degradation by PIF may also be mediated through NF-κB. The aim of the present study was to investigate the effect of PIF on the activation of NF-κB in C2C12 murine myotubes at concentrations causing an increased expression of the ubiquitin–proteasome pathway. Since EPA has been shown to attenuate the catabolic effect of PIF in murine myoblasts (Smith et al., 1999) the effect of this essential fatty acid on protein catabolism, activation of the ubiquitin–proteasome pathway and nuclear accumulation of NF-κB by PIF has been studied in myotubes to determine potential mechanisms of signal transduction.

METHODS

Purification of PIF

Pure strain female NMRI mice were obtained from our own breeding colony and were transplanted with fragments of the MAC 16 tumour into the flank by means of a trocar (Bibby et al., 1987). MAC16 tumours were originally derived from colon tumours induced by dimethylhydrazine in NMRI mice (Cowen et al., 1980). PIF was isolated from tumours that were excised, once weight loss was established (20–25%). All animal experiments have been carried out with approval from the British Home Office and the ethical guidelines followed meet the standards required by the UKCCR guidelines (Workman et al., 1998). The tumours were homogenised in 5 ml of a Tris buffer (Tris 3.05 g, EGTA 0.4755 g, DTT, 0.3865 g: (PMSF 0.1 M in 12.5 ml isopropanol in 2500 ml). All reagents were obtained from Sigma-Aldrich, Dorset, UK and Read, 2000). This suggests that the induction of protein degradation by PIF may also be mediated through NF-κB. The aim of the present study was to investigate the effect of PIF on the activation of NF-κB in C2C12 murine myotubes at concentrations causing an increased expression of the ubiquitin–proteasome pathway. Since EPA has been shown to attenuate the catabolic effect of PIF in murine myoblasts (Smith et al., 1999) the effect of this essential fatty acid on protein catabolism, activation of the ubiquitin–proteasome pathway and nuclear accumulation of NF-κB by PIF has been studied in myotubes to determine potential mechanisms of signal transduction.

Cell culture and differentiation of C2C12 myoblasts into myotubes

All experiments were performed with myotubes since they contain the myofibrillar proteins actin and myosin seen in skeletal muscle. C2C12 myoblasts were maintained in a proliferative state of growth in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5% foetal calf serum and 1% penicillin/streptomycin (Gibco Life Sciences, UK). For all experimentation, cells were differentiated into myotubes by incubation in DMEM, which had been supplemented with 2% horse serum and 1% penicillin/streptomycin.

Measurement of protein degradation

Protein degradation was determined as previously described (Gomes-Marcondes et al., 2002) in six well multiwell dishes. Just before the cells were fully differentiated, 20 μl of [3H] phenylalanine ([3H]-Phe) corresponding to 2 μCi was added to each well and the cells were incubated at 37°C in 5% CO₂ overnight in the absence of any treatment. [3H]-Phe was preprepared by adding 60 μg ‘cold’ phenylalanine to 500 μl [3H]-Phe in 4500 μl PBS. The following day (during which time myotubes would have fully formed), the media was discarded and the cells were rinsed twice in PBS. DMEM without phenol red (supplemented with 2% horse serum and 1% penicillin/streptomycin) was added following a 2 h preincubation, the media was removed and replaced with DMEM without phenol red (supplemented as previous) along with a range of concentrations of PIF with or without lactacystin (10 μM) and 2 mM ‘cold’ phenylalanine. Cells were then incubated for a further 24 h. Finally, 1 ml of supernatant was removed and added to 6 ml optiphase ‘Hi safe 3’ scintillation fluid (Fisher Chemicals, Leicester, UK). The radioactivity released was analysed using a ‘Tri-carb’ liquid scintillation analyser (United Technologies, Packard, Berks, UK). The data were the same whether expressed as total [3H]-Phe released or as a percentage of total radioactivity incorporated.

Measurement of proteasomal ‘chymotrypsin-like’ enzyme activity in C2C12 myotubes

The ‘chymotrypsin-like’ enzyme activity of the proteasome was determined fluorometrically according to the method of Orino et al. (1991). Myotubes were pretreated with EPA for 2 h prior to the addition of PIF and the EPA remained in the culture medium for the course of the experiment. After 24 h, myotubes were washed twice in ice-cold PBS and scraped into approximately 0.5 ml homogenising buffer (20 mM Tris, pH7.5, 2 mM ATP, 5 mM MgCl₂, 50 mM DTT). Samples were then sonicated for three pulses of 15 s, with 10 s intervals, with care to avoid heating, and centrifuged at 18 000 g for 10 min at 4°C to pellet insoluble material. A stock solution of substrate (10 mg N-succinyl-LLVY-7-amido-4-methyl coumarin in 600 μl dimethyl sulphoxide) was diluted 1:1000 in 100 mM Tris/HCl, pH 8.0, for use. A volume of 100 μl was added to 50–100 μl of prepared sample. A set of substrate was included which the proteasome inhibitor lactacystin (Affiniti Research Products, Exeter, Devon, UK) had been added to give a final concentration of 10 μM per well. Samples were then incubated for 2 h on ice. Fluorescence of the substrate was measured using an LS550 Luminescence Spectrometer (Perkin-Elmer) at excitation 360 nm and emission 460 nm, and values were adjusted for equal protein concentrations and for a reaction blank. The substrate concentration was saturated and the activity was linear with protein concentration.

Determination of protein concentration

Protein concentrations were determined using a standard commercially available colourimetric protein assay (Biorad, UK) according to the manufacturer’s instructions.

Western blotting protocol Myoblasts were allowed to differentiate into myotubes as above, and treated with various concentrations of PIF as indicated in the figure legends, with or without 2 h preincubation with 50 μM EPA. The media were rinsed from myotubes that were homogenised and sonicated in 300–2000 μl homogenising buffer (as described above). After centrifugation (18 000 g for 5 min) to pellet-insoluble material, the supernatant

© 2003 Cancer Research UK
was assayed for protein concentration. Homogenates were
denatured in electrophoresis sample buffer (125 mM Tris, pH 6.8,
4% SDS, 10% glycerol, 0.006% bromophenol blue, 2% mercapto-	oneanol) by heating to 95°C for 5 min and electrophoresed on a
12% SDS–polyacrylamide gel (10 cm x 10 cm) along with ‘Rainbow’
 molecular weight markers (Amersham Biosciences, UK).

Proteins were electrotransferred to a nitrocellulose membrane using
an enclosed system for 2 h at a constant voltage of 80 V. After
transfer, the membranes were rinsed in buffer (0.1% Tween
20 in PBS) and transferred to blocking buffer (5% Marvel in wash
buffer) for 1 h at room temperature. Blots were probed for 20S
proteasome subunits, p24 proteasome subunit and inhibitory
protein of NF-kB (tIkB) using appropriate antisera. Primary
antisera were diluted in blocking buffer (Rabbit polyclonal
IgG : HRP; Amersham Biosciences, UK) and added to membranes for 1 h at
room temperature with agitation, changing the wash buffer every
15–20 min. Anti-mouse or anti-rabbit IgG : HRP (horseradish
peroxidase), diluted 1 : 2000 in wash buffer, was added and
incubated for 1 h at room temperature. After incubation with
secondary antibody, the membranes were washed for a further
90 min with agitation, again changing the buffer every 15–20 min.

Proteins were detected using an ‘Enhanced Chemiluminescence’
(ECL) system (Amersham Biosciences, UK), which is based upon
the oxidation of luminol by HRP, resulting in light emission,
detected by a blue light sensitive autoradiography film. To ensure
equal loading, a parallel gel was stained with 1% Coomassie
Brilliant Blue (in 40% methanol/10% acetic acid) for 1 h.

Electrophoretic mobility shift assay (EMSA) C2C12 myotubes were
-treated with EPA and PIF as described in Figure 5A. A vehicle
control (as well as no treatment control) was included, to
determine any effects caused by the solvent. The cells were
incubated for 20 min with PIF prior to the EMSA assay.

Labelling of consensus oligonucleotides In all, 2 µl NF-kB
(1.75 pmol µl⁻¹) (Promega UK), oligonucleotide sequence 5'-AGT
TGA GGG GAC TTT CCC AGG C-3'; 3'-TCA ACT CCC CTG AAA
GGO TCC G-5' (1 µl T4 polynucleotide kinase 10 x buffer
(Promega, UK); 2 µl [γ-32P]ATP (Amersham Biosciences, UK);
1 µl T4 polynucleotide kinase (Promega, UK) were assembled in
a sterile microcentrifuge tube, the volume was adjusted to 10 µl
with nuclease-free H₂O (Promega, UK), and incubated at 37°C for 1 h.
The reaction was stopped by the addition of 2 µl 0.5 M EDTA
followed by 88 µl of TE buffer.

Preparation of nuclear proteins The cells were rinsed, scraped
and pelleted in wash buffer (10 mM HEPES/KOH pH 7.5, 10 mM
KCl, 2 mM MgCl₂, 1 mM DTT, 0.1 mM EDTA, 0.4 mM PMSF, 0.2 mM
NaF, 0.2 mM sodium orthovanadate, 0.3 mg ml⁻¹ leupeptin).
Extracts were prepared according to Johnson et al. (1996) with
modifications. The pellets were resuspended in 300 µl of the same
wash buffer and incubated on ice for 15 min. In all, 30 µl of 1%'
Triton X100' (octylphenoxypolyethoxyethanol) was then added
and the cells were lysed by vortexing. A 4 min centrifugation
at 2000 g pelleted the nuclei and the supernatant was removed.
The nuclear pellet was resuspended in 50 µl of the ice-cold high-salt
buffer (50 mM HEPES, pH 7.8, 50 mM KCl, 300 mM NaCl, 0.1 mM
EDTA, 1 mM DTT, 0.4 mM PMSF, 0.2 mM NaF, 0.2 mM sodium
orthovanadate, 10% glycerol) to solubilise nuclear proteins and the
suspension was kept on ice for 20 min with a 30 s vortex every 3–
5 min. A centrifugation at 15 500 g for 3 min yielded the superna-
tant containing the protein extract. The concentration of nuclear
extracts was measured by protein assay (as described previously).
Measurements were repeated three times to ensure the accuracy of
the assay.

DNA binding reaction Gel shift binding buffer (2 µl) (Promega,
UK) and nuclear extract (10 µg for each test) were added in a
sterile microtube and then incubated with 2 µl unlabelled NF-kB (compe-
titor control) or 2 µl of a different unlabelled oligonucleotide
(noncompetitor control). A negative control reaction was also
included, which contained gel shift binding buffer and no sample.
In total, 2 µl of [γ-32P] NF-kB was then added to tests and controls
and the volumes were equalised with nuclease-free water. The
reactions were then incubated at room temperature for 2 h. Finally,
1 µl of gel loading 10 x buffer (250 mM Tris-HCl, pH 7.5, 0.2% 
bromophenol blue, 40% glycerol) was added to the negative
control, and the reaction products were analysed via electrophor-
esis on an 8% nondenaturing polyacrylamide gel, with a native 5%
polyacrylamide stacking gel, which had been allowed to polymerise
for at least 2 h. The gels were pre-electrophoresed for 10 min at
150 mV and then electrophoresed (after the addition of samples) at
150 V for approximately 30 min, or until the bromophenol blue
dye front reached the base of the gel. The gel was then dried
between Whatman 3 MM filter paper and plastic wrap and exposed
to ‘Hyperfilm MP’ for 8–16 h at −70°C.

Statistical analysis

Data are expressed as mean ± s.e.m. and each experiment was
repeated at least three times. Differences were analysed by two-way
ANOVA followed by Tukey’s post-test. Differences were consid-
ered significant if P<0.05.

RESULTS

In the current experiments, myotubes were used as a model of
skeletal muscle, since they contain the myofibrillar proteins actin
and myosin not found in myoblasts. When C2C12 murine myotubes
labelled with [³H] phenylalanine were treated with PIF for 24 h,
there was an increase in total protein degradation, as evidenced by
increased release of radiolabel (Figure 1). The maximal protein
breakdown was seen at concentrations of PIF between 2 and 16 nM,
with a maximal peak of stimulatory activity (41% increase over

![Figure 1](image-url)
control) at 4 nM PIF. These concentrations are in the range expected from maximal tumour release into the circulation (35 nM) (Todorov et al, 1996a). Protein degradation was attenuated in the presence of the highly specific and irreversible proteasome inhibitor lactacystin, which does not inhibit lysosomal protein degradation (Fenteany and Schreiber, 1998) at a concentration of 10 μM (Figure 1), indicating that the elevated catabolism was due to increased proteasome activity. There was no effect of lactacystin on cell viability. Pilot experiments suggested that this concentration was sufficient to attenuate proteasome activity. PIF induced an increase in the chymotrypsin-like activity of the proteasome (the dominant catalytic activity of the β-subunits), with an increase of more than 10-fold in the presence of 4 nM PIF (Figure 2). The effect was completely abolished in the presence of lactacystin, confirming the specificity of the response, and the data presented in Figure 2 represent the lactacystin-suppressible activity. The PIF-induced increase in chymotrypsin-like activity of the proteasome was also attenuated by 50 μM EPA (Figure 2), which has also been shown to attenuate protein catabolism induced by PIF in C2C12 myoblasts (Smith et al, 1999). Lower concentrations of EPA (25 μM) were ineffective. The plasma concentration of EPA in humans consuming therapeutic levels of this fatty acid might be expected to be in the range 100–200 μM. As with protein degradation, chymotrypsin-like activity exhibited a bell-shaped dose–response curve. A similar effect was observed for expression of 20S proteasome subunits as detected by Western blotting (Figure 3), although there was no effect on degradation, chymotrypsin-like activity exhibited a bell-shaped dose–response curve. A similar effect was observed for expression of 20S proteasome subunits as detected by Western blotting (Figure 3), although there was no effect on expression of p42, an ATPase subunit of the 19S regulator (Figure 3C). After 24 h incubation with PIF, maximal increase in expression was seen between 4 and 16 nM PIF with an almost two-fold increase at 4 nM PIF (Figure 3B and D). Myotubes treated with 50 μM EPA for 2 h prior to the addition of PIF showed no increase in the expression of 20S β-subunits at any PIF concentration (Figure 3), although there was no effect on expression of p42 at the higher concentrations of PIF. These results confirm the ability of EPA to attenuate the increased expression of 20S proteasome subunits induced by PIF.

A time course for the effect of PIF on IkBα levels in C2C12 myotubes is shown in Figure 4A. There was a transient decrease in cytosolic IkBα levels after 30 min incubation with PIF at 4 nM, but not at 40 nM. When analysed densitometrically, the level of IkBα was found to decrease by 75% from the control value within 30 min of the addition of 4 nM PIF (Figure 4B). The level of IkBα returned to normal at 60 min and remained at this level indicating that the cell had recovered. When treated with a wider concentration range of PIF there was a decrease in IkBα levels in all myotubes treated with all concentrations of PIF inducing protein degradation (Figure 4C). Thus, after 30 min there was a decrease of 99.9% at 2 nM PIF, 89.7% at 4 nM PIF and 87.1% at 8 nM PIF, as determined by densitometric analysis, but no change at 20 nM PIF (Figure 4D). Depletion of IkB from the cytosol was not seen in myotubes pretreated with EPA, suggesting an effect of EPA in stabilising the NFκB/IκB complex in the cytoplasm.

Figure 2 Effect of PIF on the chymotrypsin-like enzyme activity in C2C12 myotubes in the absence (black boxes) or presence (grey boxes) of 50 μM EPA (grey boxes). The data are expressed as mean ± s.e.m. where n = 9 and the values represent the activity inhibited by 10 μM lactacystin. The differences from control are indicated as a, P<0.05 and b, P<0.001, while differences in the presence of EPA are indicated as c, P<0.05 and d, P<0.001.

Figure 3 Western blot analysis of 20S proteasome β-subunit expression (A) or (C) the 19S subunit, p42 in C2C12 myotubes 24 h after addition of PIF alone at 0 nM (lane 1), 2 nM (lane 2), 4 nM (lane 3), 8 nM (lane 4), 16 nM (lane 5) or 40 nM (lane 6) or after pretreatment with 50 μM EPA for 2 h and subsequent treatment with PIF at 0 nM (lane 7), 2 nM (lane 8), 4 nM (lane 9), 8 nM (lane 10), 16 nM (lane 11) and 40 nM (lane 12). (B) Densitometric analysis of the blot shown in (A), n = 2. (D) Densitometric analysis of the blot shown in (C), n = 2. Values shown are in the absence (black boxes) or presence (stippled boxes) of 50 μM EPA. Differences from control are shown as a, P<0.001, while differences from PIF-treated cells are shown as b, P<0.001.
The effect of PIF on NF-κB activation and accumulation in the nucleus was determined by EMSA. Proteolysis-inducing factor stimulated an increased nuclear migration of NF-κB at concentrations between 2 and 8 nM (Figure 5A and B) but not at higher concentrations. Only one sequence specific shift was identified by competition assays, which may suggest stimulation of a single NF-κB binding site.

**Figure 4** (A) The effect of PIF on IκBα expression in C2C12 myotubes at 30, 60 and 120 min as determined by Western blotting. Lanes 1, 2 and 3 represent 0, 4 and 20 nM PIF after 30 min; lanes 4–6 after 60 min and lanes 7–9 after 120 min. (B) Densitometric analysis of the blot shown in (A), n=2. Differences from control are shown as a, P<0.001. (C) The effect of PIF on IκBα expression in C2C12 myotubes after 30 min in the absence (lanes 1–5) or presence (lanes 6–10) of 50 μM EPA added 2 h prior to PIF. The lanes represent the following concentrations of PIF: 1 and 6, 0 nM; 2 and 7, 2 nM; 3 and 8, 4 nM; 4 and 9, 8 nM and 5 and 10, 20 nM. (D) Densitometric analysis of the blot shown in (C), n=2. Differences from control are shown as a, P<0.001.

**Figure 5** (A) Effect of PIF on the electrophoretic mobility of (γ32P)NF-κB in C2C12 myotubes in the absence (lanes 1–5) and presence (lanes 6–10) of 50 μM EPA. The following additions were made: lanes 1 and 60 nM PIF; lanes 2 and 7, 4 nM PIF; lanes 3 and 8, 8 nM PIF, lanes 4 and 9, 16 nM PIF and lanes 5 and 10, 20 nM PIF. Lane 11 contains a competitor, that is an equal concentration of unlabelled NF-κB, while lane 12 contains a noncompetitor, an equal concentration of an unlabelled, unrelated oligonucleotide, usually AP2. (B) Densitometric analysis of the blot shown in (A). Values shown are in the absence (black boxes) or presence (hatched boxes) of 50 μM EPA. The blot shown is representative of three separate blots performed on different occasions. (C) The effect of SN50 on PIF-induced upregulation of the chymotrypsin-like activity of the proteasome measured after 24 h incubation. Solid boxes indicate PIF alone, hatched boxes indicate PIF+18 μM SN50. The SN50 was added 2 h prior to PIF and remained in the culture medium throughout the experiment. Sample size per treatment group n=9 and the experiment was repeated twice. Differences from control and SN50 treated cells are shown as c, P<0.001.
dimer pair by PIF. The specificity of the band to NF-κB was confirmed from preliminary experiments using HeLa nuclear extracts and myotubes exposed to endotoxin. The increased nuclear levels of NFκB were not seen when PIF was added to myotubes pretreated with 50 μM EPA (Figure 5A). The increased levels of NFκB demonstrated in the nucleus in response to PIF and the attenuation of this by EPA correspond to those concentrations which induce both degradation of IκBz and increased proteasome activity. The NFκB inhibitor peptide, SN50, also attenuated the PIF-induced increase in chymotrypsin-like enzyme activity (Figure 5B) and reduced nuclear NFκB in the presence of 4 μM PIF by 80%. This suggests that NFκB may be involved in the PIF-induced increase in proteasome expression.

**DISCUSSION**

In vivo studies in mice bearing a cachexia-inducing colon adenocarcinoma (MAC16) have shown EPA to attenuate effectively the development of host weight loss in a dose-dependent manner, with preservation of both adipose tissue and skeletal muscle mass (Beck et al., 1991). EPA has also been shown to stabilise body weight in weight-losing patients with advanced pancreatic cancer (Wigmore et al., 2000). Animals bearing the MAC16 tumour showed a decreased protein synthesis and an increased protein degradation in skeletal muscle, and treatment with EPA significantly reduced protein degradation without an effect on protein synthesis (Beck et al., 1991). This effect has been shown to occur by downregulation of the increased expression of the regulatory subunit (Beck et al., 1998) that prevents the degradation of IκBz by antagonising the interaction of NFκB protein with an NFκB response element in the C3 subunit promoter region. L6 myotubes that had been heat shocked were protected from the catabolic effects of dexamethasone, together with attenuation of the downregulation of NFκB (Luo et al., 2001). In sepsis, there is an activated NFκB upregulation of NFκB activity in skeletal muscle, followed by inhibited NFκB at 16 h (Penner et al., 2001). The latter effect was probably due to glucocorticoids since the glucocorticoid receptor antagonist RU38486 inhibited NFκB.

However, other studies suggest a positive correlation between activation of NFκB and expression of genes of the ubiquitin–proteasome proteolytic pathway. Li et al. (1998) showed that differentiated murine myotubes treated with tumour necrosis factor x (TNFα) lost total protein and adult myosin heavy chain, together with activation of NFκB. They showed that the activity of NFκB could be correlated to an increased ubiquitin conjugation to muscle proteins, and a subsequent rise in ubiquitin mRNA, suggesting that NFκB might function to increase expression of members of the ubiquitin–proteasome pathway in skeletal muscle. This conclusion was endorsed by studies using C57Bl mice transfected with viral plasmid constructs that overexpress mutant IκBz proteins that are insensitive to degradation by the ubiquitin–proteasome pathway (Li and Read, 2000). Total protein content and myosin heavy-chain levels were found to be unaltered in response to TNFα, suggesting that NFκB is an essential mediator of TNFα-induced protein catabolism in differentiated muscle cells. It is possible that this apparent disparity among the literature may reflect cell-system specific recruitment of NFκB subunits, which may have different biochemical effects. Indeed, it has already been suggested that NFκB may be an intermediate in both catabolic and anabolic pathways (Mitch and Price, 2001).

The present study provides some support to the work of Li and Read (2000) that NFκB provides a positive signal for protein degradation in skeletal muscle and may act to increase expression of proteasome subunits and ubiquitin-dependent proteolysis in murine myotubes. Certainly, nuclear accumulation of NFκB is increased by PIF at the same concentrations that induce protein catabolism and upregulation of 20S proteasome x-subunit expression and this is accompanied by the disappearance of IκBz from the cytosol. In addition, the NFκB inhibitor peptide, SN50, which competes for the nuclear translocation sequences of NFκB, attenuated both the increased DNA binding of NFκB induced by PIF and the increased proteasome chymotrypsin-like enzyme activity. Both proteasome expression and nuclear accumulation of NFκB induced by PIF were also attenuated by EPA, which acted to prevent the degradation of IκBz, possibly by stabilising the NFκB/IκB complex directly. EPA may exert its effects upon the inhibition of IκBz degradation through interference with upstream effectors, like IκB kinase kinase (IKK), possibly by direct binding via a thioester or O-ester linkage as occurs in platelets (Muszbek and Laposata, 1993). Alternatively, the effect may be mediated through inhibition of 15-HEPE production (Smith et al., 1999), since we have shown 15-HEPE to also increase NFκB nuclear binding and IκBz degradation at the same concentrations that cause an increase in protein degradation (unpublished results). It is possible...

© 2003 Cancer Research UK

British Journal of Cancer (2003) 89(6), 1116–1122
that 15-HETE could result in the generation of reactive oxygen species, which might regulate the redox-sensitive NF-κB (Bonizzi et al. 1996; Li et al. 1998), possibly through oxidation of constituent proteins that augment, or promote the release from or degradation of IκB.

Although the present study does not confirm a role for NF-κB in ubiquitin–proteasome proteolysis, it does suggest that NF-κB is activated prior to the induction of this pathway by PIF. Further studies are in progress to establish the role of NF-κB in proteasome proteolysis.

ACKNOWLEDGEMENTS

This work has been supported by a grant from the Lustgarten Foundation for Pancreatic Cancer Research.